RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Operating income

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndOperating income (Million USD)YoY (%)
Dec 31, 20243,991-1.39%
Dec 31, 20234,047-14.60%
Dec 31, 20224,739-47.03%
Dec 31, 20218,947+150.15%
Dec 31, 20203,577+61.85%
Dec 31, 20192,210-12.81%
Dec 31, 20182,534+21.87%
Dec 31, 20172,080+56.27%
Dec 31, 20161,331+6.30%
Dec 31, 20151,252+49.32%
Dec 31, 2014838+10.32%
Dec 31, 2013760+66.05%
Dec 31, 2012458-323.10%
Dec 31, 2011-205+110.48%
Dec 31, 2010-97

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)